Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.27
NAS:BSPM's Cash-to-Debt is ranked lower than
81% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NAS:BSPM: 0.27 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BSPM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 29.22 Max: No Debt
Current: 0.27
Equity-to-Asset 0.84
NAS:BSPM's Equity-to-Asset is ranked higher than
85% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NAS:BSPM: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BSPM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79  Med: 0.87 Max: 0.96
Current: 0.84
0.79
0.96
Piotroski F-Score: 5
Altman Z-Score: -2.01
Beneish M-Score: -6.96
WACC vs ROIC
15.66%
-66.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -757.59
NAS:BSPM's Operating Margin % is ranked lower than
93% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. NAS:BSPM: -757.59 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BSPM' s Operating Margin % Range Over the Past 10 Years
Min: -757.59  Med: 19.75 Max: 30.5
Current: -757.59
-757.59
30.5
Net Margin % -826.91
NAS:BSPM's Net Margin % is ranked lower than
93% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NAS:BSPM: -826.91 )
Ranked among companies with meaningful Net Margin % only.
NAS:BSPM' s Net Margin % Range Over the Past 10 Years
Min: -826.91  Med: 13.24 Max: 24.95
Current: -826.91
-826.91
24.95
ROE % -71.45
NAS:BSPM's ROE % is ranked lower than
90% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NAS:BSPM: -71.45 )
Ranked among companies with meaningful ROE % only.
NAS:BSPM' s ROE % Range Over the Past 10 Years
Min: -71.45  Med: 17.78 Max: 34.28
Current: -71.45
-71.45
34.28
ROA % -61.43
NAS:BSPM's ROA % is ranked lower than
91% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NAS:BSPM: -61.43 )
Ranked among companies with meaningful ROA % only.
NAS:BSPM' s ROA % Range Over the Past 10 Years
Min: -61.43  Med: 16.11 Max: 30.2
Current: -61.43
-61.43
30.2
ROC (Joel Greenblatt) % -153.63
NAS:BSPM's ROC (Joel Greenblatt) % is ranked lower than
84% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. NAS:BSPM: -153.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BSPM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -153.63  Med: 50.12 Max: 96.91
Current: -153.63
-153.63
96.91
3-Year Revenue Growth Rate -30.20
NAS:BSPM's 3-Year Revenue Growth Rate is ranked lower than
94% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NAS:BSPM: -30.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BSPM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.2  Med: -13.6 Max: 56.5
Current: -30.2
-30.2
56.5
3-Year EBITDA Growth Rate -12.70
NAS:BSPM's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. NAS:BSPM: -12.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BSPM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.6  Med: -12.7 Max: 49.8
Current: -12.7
-45.6
49.8
3-Year EPS without NRI Growth Rate -8.00
NAS:BSPM's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NAS:BSPM: -8.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BSPM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: -8 Max: 49.1
Current: -8
-66.7
49.1
GuruFocus has detected 5 Warning Signs with Biostar Pharmaceuticals Inc $NAS:BSPM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BSPM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BSPM Guru Trades in Q4 2015

Jim Simons 707,370 sh (-85.47%)
» More
Q1 2016

BSPM Guru Trades in Q1 2016

Jim Simons 104,856 sh (+3.76%)
» More
Q2 2016

BSPM Guru Trades in Q2 2016

Jim Simons 105,956 sh (+1.05%)
» More
Q3 2016

BSPM Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BSPM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB, AMEX:CPHI, OTCPK:INNV, NAS:TNXP, OTCPK:SUWN, NAS:ALQA, NAS:IMNP, NAS:NVGN, AMEX:AXN, NAS:PRPH, NAS:OASM, AMEX:NNVC, OTCPK:BIOYF, NAS:ALIM, NAS:ZGNX, NAS:NBRV, NAS:RMTI, NAS:ASMB » details
Traded in other countries:7BNB.Germany,
Biostar Pharmaceuticals Inc, through its subsidiaries is engaged in the business of developing, manufacturing and marketing over-the-counter and prescription pharmaceutical products in the Peoples Republic of China.

Biostar Pharmaceuticals Inc is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the Peoples Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter (OTC) medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.

Ratios

vs
industry
vs
history
PB Ratio 0.16
BSPM's PB Ratio is ranked higher than
100% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. BSPM: 0.16 )
Ranked among companies with meaningful PB Ratio only.
BSPM' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.27 Max: 3.22
Current: 0.16
0.06
3.22
PS Ratio 1.27
BSPM's PS Ratio is ranked higher than
79% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. BSPM: 1.27 )
Ranked among companies with meaningful PS Ratio only.
BSPM' s PS Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.35 Max: 2.44
Current: 1.27
0.13
2.44
Price-to-Free-Cash-Flow 0.71
BSPM's Price-to-Free-Cash-Flow is ranked higher than
100% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.25 vs. BSPM: 0.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSPM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.5  Med: 3.69 Max: 1373.75
Current: 0.71
0.5
1373.75
Price-to-Operating-Cash-Flow 0.71
BSPM's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.28 vs. BSPM: 0.71 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSPM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.5  Med: 2.75 Max: 19.94
Current: 0.71
0.5
19.94
Current Ratio 1.12
BSPM's Current Ratio is ranked lower than
84% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. BSPM: 1.12 )
Ranked among companies with meaningful Current Ratio only.
BSPM' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 4.96 Max: 19.49
Current: 1.12
1.12
19.49
Quick Ratio 1.05
BSPM's Quick Ratio is ranked lower than
75% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. BSPM: 1.05 )
Ranked among companies with meaningful Quick Ratio only.
BSPM' s Quick Ratio Range Over the Past 10 Years
Min: 1.05  Med: 4.91 Max: 19.17
Current: 1.05
1.05
19.17
Days Inventory 64.05
BSPM's Days Inventory is ranked higher than
77% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. BSPM: 64.05 )
Ranked among companies with meaningful Days Inventory only.
BSPM' s Days Inventory Range Over the Past 10 Years
Min: 6.29  Med: 10.35 Max: 64.05
Current: 64.05
6.29
64.05
Days Sales Outstanding 569.61
BSPM's Days Sales Outstanding is ranked lower than
99% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. BSPM: 569.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSPM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 94.72  Med: 135.56 Max: 569.61
Current: 569.61
94.72
569.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.60
BSPM's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. BSPM: -15.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSPM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.1  Med: -10.55 Max: -8.5
Current: -15.6
-18.1
-8.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.56
BSPM's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. BSPM: 6.56 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BSPM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.25  Med: 0.64 Max: 10.94
Current: 6.56
0.25
10.94
Price-to-Tangible-Book 0.18
BSPM's Price-to-Tangible-Book is ranked higher than
99% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. BSPM: 0.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BSPM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.11  Med: 0.33 Max: 3.48
Current: 0.18
0.11
3.48
Price-to-Intrinsic-Value-Projected-FCF 0.08
BSPM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. BSPM: 0.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSPM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 0.14 Max: 0.26
Current: 0.08
0.05
0.26
Price-to-Median-PS-Value 3.60
BSPM's Price-to-Median-PS-Value is ranked lower than
92% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. BSPM: 3.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSPM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.95 Max: 6
Current: 3.6
0.38
6
Earnings Yield (Greenblatt) % -384.13
BSPM's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. BSPM: -384.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSPM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -400  Med: 27 Max: 7733
Current: -384.13
-400
7733

More Statistics

Revenue (TTM) (Mil) $3.91
EPS (TTM) $ -14.65
Beta1.42
Short Percentage of Float18.17%
52-Week Range $1.08 - 7.06
Shares Outstanding (Mil)2.64
» More Articles for NAS:BSPM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ANADIGICS Inc., Biostar Pharmaceuticals Inc., Astrotech Corp. May 30 2011 

More From Other Websites
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 24 2017
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 09 2017
BIOSTAR PHARMACEUTICALS, INC. Financials Nov 26 2016
BioStar Pharmaceuticals, Inc. :BSPM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23,... Nov 23 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended September 30,... Nov 21 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended September 30,... Nov 21 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 21 2016
Biostar Pharmaceuticals Completes Previously Announced Registered Direct Financing Nov 14 2016
Biostar Pharmaceuticals Completes Previously Announced Registered Direct Financing Oct 18 2016
Why Biostar Pharmaceuticals Inc.(BSPM), Telefonaktiebolaget LM Ericsson (ERIC), and Three Other... Oct 12 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Oct 12 2016
Biostar Announces Execution of Agreement for $1.91 Million Registered Direct Offering of Shares of... Oct 12 2016
Biostar Pharma Skyrockets on New Chinese Product Launch Oct 11 2016
Why Biostar Pharmaceuticals Inc. (BSPM), Nova Lifestyle Inc. (NVFY) & Three Other Stocks Are Trading... Oct 11 2016
Biostar to Launch a New Product Aimed at Treating Effects of Rhinitis and Sinusitis Oct 11 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Sep 22 2016
Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co.,... Sep 22 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 22 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2016 Aug 22 2016
BioStar Pharmaceuticals, Inc. :BSPM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 Jun 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)